GlobeNewswire
BBOT Announces Multiple Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
📈
AI Sentiment
Highly Positive
8/10
- Home
- BBOT
as of 03-24-2026 3:55pm EST
$8.70
$0.11
-1.25%
BridgeBio Oncology Therapeutics Inc, formerly BridgeBio Oncology Therapeutics is a clinical-stage biotechnology company that aims to transform the lives of patients with cancers driven by RAS and PI3Ka, the two frequently mutated oncogenes.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 1.1B | IPO Year: | N/A |
| Target Price: | $24.00 | AVG Volume (30 days): | 184.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | N/A | EPS Growth: | N/A |
| 52 Week Low/High: | $8.67 - $14.87 | Next Earning Date: | 03-05-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | N/A | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Latest BridgeBio Oncology Therapeutics Inc. News
BBOT Breaking Stock News: Dive into BBOT Ticker-Specific Updates for Smart Investing
Compare BBOT vs Leading Stocks
See how BBOT stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "BBOT BridgeBio Oncology Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.